Geron Corporation

Geron is a hematology-focused biopharmaceutical company developing and commercializing therapies for people living with blood cancer. Its work centers on telomerase inhibition and imetelstat, including treatment areas such as lower-risk myelodysplastic syndromes and myelofibrosis. Following the FDA approval of RYTELO in 2024, Geron became a commercial-stage biotechnology company; it describes its mission as helping patients live with more energy, fewer limitations, and greater possibility.